Platform
- Home
- Product Pipeline
- Patent Portfolio
For many new drug development companies, patent strategy is a critical component of their drug development programs. A well-designed patent strategy comprises a series of measures implemented by a company to strengthen its industry leadership position and to protect its hard-earned advanced technologies or inventions within its areas of expertise.When selecting drug candidates, the Company and its subsidiaries conduct rigorous and objective feasibility assessments in advance, covering mechanism of action, market potential, technical considerations, regulatory aspects, and financial factors. Candidate products must meet the following criteria: (1) a clearly defined mechanism of action; (2) targeting a niche market addressing unmet medical needs; and (3) possessing a high technological barrier to entry.
These criteria are intended to ensure product competitiveness. Through an integrated resource allocation and specialized division-of-labor model, the Company formulates and executes differentiated technology derivation strategies for each project, establishing a comprehensive new drug development pipeline. By leveraging multinational, multicenter clinical trials and robust patent protection, the Company aims to enhance overall product value.
To build a strong intellectual property portfolio, the Company has established incentive mechanisms to encourage employees to submit invention disclosures. At the same time, it has implemented a systematic patent and intellectual property management framework to control both the quantity and quality of patent applications. The Company employs dedicated intellectual property and technical professionals who maintain close communication and technical exchanges with patent law firms and patent authorities in major domestic and international markets. These efforts help patent examiners gain a deeper understanding of Senhwa’s technologies, thereby improving examination efficiency and securing high-quality patent protection.
The Company and its subsidiaries possess comprehensive global rights of independent use, including development, manufacturing, commercialization, and out-licensing. A complete patent portfolio has been established across major pharmaceutical markets, including the United States, Canada, the European Union (17 individual countries), the United Kingdom, Brazil, Japan, Australia, New Zealand, Russia, India, Israel, South Korea, Taiwan, China, Hong Kong, Thailand, Indonesia, Vietnam, the Philippines, Singapore, and Malaysia. As of December 30, 2025, the Company holds a total of 163 granted patents and 45 pending applications, covering composition of matter patents, process patents, pharmaceutical composition patents, polymorph patents, dosage form patents, indication patents, and combination therapy patents.
.